UroGen Pharma Shares Fall 4.7% After Q3 Results Miss Estimates
UroGen Pharma shares were down 4.7% in early trading after its third-quarter results missed estimates.
Related stories
North Media Reports Q3 Revenue of DKK 307.5 Million
M impact | EQUITY | Nov 04, 2026, 03:31 PM UTC
OPENLANE Reports Third-Quarter Revenue of $561.2 Million
Third-quarter 2026 revenue rose 12.6% year over year to $561.2 million. Net income attributable to common stockholders increased 62% to $44.7 million, while diluted EPS rose 44% to
M impact | EQUITY | Nov 04, 2026, 03:21 PM UTC
Total Transport Systems reports quarterly revenue of 2.84 billion rupees
M impact | EQUITY | Nov 04, 2026, 03:21 PM UTC
Vertiv Signs Three-Year Power Semiconductor Supply Agreement With Infineon
Vertiv said it signed a three-year supply agreement with Infineon Technologies for power semiconductors.
M impact | EQUITY | Nov 04, 2026, 03:20 PM UTC
North Media Swings to Operating Profit in Q3 2026
North Media returned to operating profit in the third quarter of 2026.
M impact | EQUITY | Nov 04, 2026, 03:20 PM UTC
India's BSE Reports Higher Second-Quarter Profit, Signals Derivatives Recovery
BSE reported a jump in second-quarter profit and signaled a recovery in derivatives.
M impact | EQUITY | Nov 04, 2026, 03:20 PM UTC